NV reMYND is a biotech spin-off of the University of Leuven (Belgium).

reMYND is active in the field of Alzheimer’s disease and Parkinson’s disease. In 2004 reMYND received the Flanders' Most Innovative Start-up Award. The company consists of 2 independent units :

• Contract Research Unit mainly focused on Alzheimer transgenic mouse models with amyloid pathology.
• Drug Discovery Unit focused on tau and α-synuclein as targets.
• Licensing opportunity : RadarScreen